Betaxolol is a USFDA-approved safe & selective β1 receptor blocker. It decreases aqueous humour production by blocking selectively the beta-1 receptor in the ciliary body as a result, IOP is lowered. Also, Betaxolol shows Ca++ channel blocking property. Due to this property, Betaxolol exerts neuroprotective action. The onset of action with Betaxolol can generally be noted within 30 minutes and the IOP lowering effect can usually be detected 2 hours after topical administration. A single dose provides a 12-hour reduction in intraocular pressure (IOP) and twice daily administration maintains the IOP lowering efficacy 27.77% from baseline.
Betaxol is manufactured with European source raw material. Betaxol is indicated for the reduction of elevated intraocular pressure in patients with ocular hypertension and chronic open-angle glaucoma.
FR
DE